PYXS — Pyxis Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $267.74m
- $178.85m
- $16.15m
Annual cashflow statement for Pyxis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.8 | -76 | -121 | -73.8 | -77.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.012 | 33.3 | 26.2 | 12.8 | 28.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.29 | 6.68 | 4.5 | -11.7 | -9.66 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -10.1 | -35.3 | -89.3 | -70.7 | -57.7 |
| Capital Expenditures | -1.48 | -0.54 | -6.4 | -6.73 | -0.237 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.05 | 0 | -98.1 | 8.39 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.48 | -0.59 | -6.4 | -105 | 8.15 |
| Financing Cash Flow Items | — | — | — | -0.313 | -0.24 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.035 | 304 | 0.183 | 5.93 | 59.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.5 | 268 | -95.6 | -170 | 9.81 |